Warfarin: An inconvenient truth

Melina Gattellari; John Worthington; Nicholas Zwar

doi:10.1161/STROKEAHA.108.527903

Warfarin: An inconvenient truth

Melina Gattellari^*
, John Worthington
, Nicholas Zwar

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Research

7 Citations (Scopus)

Abstract

In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.

Original language	English
Pages (from-to)	5-7
Number of pages	3
Journal	Stroke
Volume	40
Issue number	1
DOIs	https://doi.org/10.1161/STROKEAHA.108.527903
Publication status	Published - 1 Jan 2009
Externally published	Yes

Access to Document

10.1161/STROKEAHA.108.527903Licence: Free to read

Cite this

@article{02515ff95fd6456e9dc03027b6aa355a,

title = "Warfarin: An inconvenient truth",

abstract = "In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.",

author = "Melina Gattellari and John Worthington and Nicholas Zwar",

year = "2009",

month = jan,

day = "1",

doi = "10.1161/STROKEAHA.108.527903",

language = "English",

volume = "40",

pages = "5--7",

journal = "Stroke",

issn = "0039-2499",

publisher = "Wolters Kluwer Health",

number = "1",

}

TY - JOUR

T1 - Warfarin

T2 - An inconvenient truth

AU - Gattellari, Melina

AU - Worthington, John

AU - Zwar, Nicholas

PY - 2009/1/1

Y1 - 2009/1/1

N2 - In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.

AB - In 1989, the Copenhagen AFASAK study reported results from the first randomized, placebo-controlled trial evaluating adjusted-dose warfarin and aspirin in the prevention of stroke for nonvalvular atrial fibrillation (NVAF). Like the 5 randomized, placebo-controlled trials that came after it, the Copenhagen AFASAK study demonstrated a reduction in embolic events in patients taking warfarin. Today, the weight of evidence from 18 trials comparing warfarin with either placebo or antiplatelet drugs overwhelmingly favors the use of warfarin for stroke prevention in NVAF.

UR - https://www.scopus.com/pages/publications/60549093415

U2 - 10.1161/STROKEAHA.108.527903

DO - 10.1161/STROKEAHA.108.527903

M3 - Editorial

C2 - 18757283

AN - SCOPUS:60549093415

SN - 0039-2499

VL - 40

SP - 5

EP - 7

JO - Stroke

JF - Stroke

IS - 1

ER -

Warfarin: An inconvenient truth

Abstract

Access to Document

Other files and links

Fingerprint

Cite this